Late-breaking Novo Nordisk (NVO) extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia® plus metformin at 52 weeks.
Key findings from the study include:
- Patients treated with 1.2 mg and 1.8 mg of Victoza® experienced greater reductions in A1c than those treated with Januvia® 100 mg (-1.3% and -1.5% versus -0.9%)
- Victoza® provided greater weight loss versus patients treated with Januvia® (2.8 kg [6.16 lbs] and 3.7 kg [8.14 lbs] for 1.2 mg and 1.8 mg respectively, 1.2 kg [2.64 lbs] for Januvia®)
- Victoza® provided greater change from baseline FPG readings than those treated with Januvia® (-1.7 mmol/L and -2.0 mmol/L for 1.2 mg and 1.8 mg respectively, versus -0.6 mmol/L)
- Patients treated with Victoza® 1.8 mg reported significantly greater treatment satisfaction than those treated with Januvia®
"What is so encouraging about these data is that Victoza® at both doses was more effective than Januvia® at achieving blood sugar control in people with type 2 diabetes over a period of one year. Patients who began the trial with higher A1c levels achieved greater reductions in A1c with treatment with Victoza®," said Dr. Richard Pratley, of the Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington. "Although Victoza® is not indicated for the management of obesity, the study showed that Victoza® provided greater weight loss than Januvia®, which is a benefit for those patients struggling to maintain a healthy weight."
In addition, significantly more patients treated with Victoza® achieved the ADA recommended A1c target of <7.0%. Nearly twice as many study participants on Victoza® reached the ADA goal compared to the Januvia® group (50% and 63% in the 1.2mg and 1.8mg Victoza® groups versus 27% in the Januvia® group).